diabetes. PLoS One. 2013; 8:e56488.
19 19. Knip M, Akerblom HK, Al Taji E et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial. JAMA. 2018; 319:38–48.
20 20. Hummel S, Pflüger M, Hummel M et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes. Diabetes Care. 2011; 34:1301–1305.
21 21. Beyerlein A, Chmiel R, Hummel S et al. Timing of gluten introduction and islet autoimmunity in young children: Updated results from the Babydiet study. Diabetes Care. 2014; 37:e194–195.
22 22. Uusitalo U, Lee HS, Andren Aronsson C et al. Early infant diet and islet autoimmunity in the TEDDY study. Diabetes Care. 2018; 41:522–530.
23 23. Uusitalo U, Liu X, Yang J et al. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 2016; 170:20–28.
24 24. Sørensen IM, Joner G, Jenum PA et al. Serum long chain n‐3 fatty acids (EPA and DHA) in the pregnant mother are independent of risk of type 1 diabetes in the offspring. Diabetes. Metab. Res. Rev. 2012; 28:431–438.
25 25. Näntö‐Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double‐blind, randomised controlled trial. Lancet. 2008; 372:1746–1755.
26 26. Bingley PJ and Gale EAM. Progression to type 1 diabetes in islet cell antibody‐positive relatives in the European Nicotinamide Diabetes Intervention Trial: The role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006; 49:881–890.
27 27. Beik P, Ciesielska M, Kucza M et al. Prevention of type 1 diabetes: Past experiences and future opportunities. J. Clin. Med. 2020; 9.
28 28. Skyler JS, Krischer JP, Wolfsdorf J. Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial‐type 1. Diabetes Care. 2005; 28:1068–1076.
29 29. Vehik K, Cuthbertson D, Ruhlig H et al. Long‐term outcome of individuals treated with oral insulin: Diabetes Prevention Trial‐Type 1 (DPT‐1) oral insulin trial. Diabetes Care. 2011; 34:1585–1590.
30 30. Ryhänen SJ, Harkonen T, Siljander H et al. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA‐conferred susceptibility to type 1 diabetes. Diabetes Care. 2011; 34:1383–1388.
31 31. Gubitosi‐Klug RA, Lachin JM, Backlund JYC et al. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30‐year follow‐up. Diabetes Care. 2016; 39(5):686–693.
32 32. Lachin JM, Bebu I, Bergenstal RM et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 2017; 40:777–783.
33 33. Bone RN and Evans‐Molina C. Combination immunotherapy for type 1 diabetes. Current Diabetes Reports. 2017; 17:50 .
34 34. Atkinson MA, Von Herrath M, Powers AC, and Clare‐Salzler M. Current concepts on the pathogenesis of type 1 diabetes‐considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015; 38:979–988.
35 35. Rak K and Bronkowska M. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of type 1 diabetes mellitus: A narrative review. Molecules. 2018; 24:24.
36 36. Gabbay MAL, Sato MN, Finazzo C et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β‐cell function in new‐onset type 1 diabetes mellitus. Arch. Pediatr. Adolesc. Med. 2012; 166:601–607.
37 37. Bogdanou D, Penna‐Martinez M, Filmann N et al. T‐lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover. Diabetes. Metab. Res. Rev. 2017; 33.
38 38. Treiber G, Prietl B, Frohlich‐Reiterer E et al. Cholecalciferol supplementation improves suppressive capacity of regulatory T‐cells in young patients with new‐onset type 1 diabetes mellitus: A randomized clinical trial. Clin. Immunol. 2015; 161:217–224.
39 39. Ataie‐Jafari A, Loke SC, Rahmat AB et al. A randomized placebo‐controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin. Nutr. 2013; 32:911–917.
40 40. Pitocco D, Crino A, Di Stasio E et al. The effects of calcitriol and nicotinamide on residual pancreatic β‐cell function in patients with recent‐onset Type 1 diabetes (IMDIAB XI). Diabet. Med. 2006; 23:920–923.
41 41. Bizzarri C, Pitocco D, Napoli N et al. No protective effect of calcitriol on β‐cell function in recent‐onset type 1 diabetes: The IMDIAB XIII trial. Diabetes Care. 2010; 33:1962–1963.
42 42. Herold KC, Hagopian W, Auger JA et al. Anti‐CD3 monoclonal antibody in new‐onset type 1 diabetes mellitus. N. Engl. J. Med. 2002; 346:1692–1698.
43 43. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3‐antibody therapy in new‐onset type 1 diabetes. N. Engl. J. Med. 2005; 352:2598–2608.
44 44. Herold KC, Bundy BN, Long SA et al. An anti‐CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 2019; 381:603–613.
45 45. Aronson R, Gottlieb PA, Christiansen JS et al. Low‐dose otelixizumab anti‐CD3 monoclonal antibody DEFEND‐1 study: Results of the randomized phase III study in recent‐onset human type 1 diabetes. Diabetes Care 2014; 37:2746–2754.
46 46. Pescovitz MD, Greenbaum CJ, Bundy B et al. B‐lymphocyte depletion with rituximab and β‐cell function: Two‐year results. Diabetes Care. 2014; 37:453–459.
47 47. Orban T, Bundy B, Becker DJ et al. Co‐stimulation modulation with abatacept in patients with recent‐onset type 1 diabetes: A randomised double‐masked controlled trial. Lancet. 2011; 378:412–419.
48 48. Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 2012; 366:433–442.
49 49. Ludvigsson J. Autoantigen treatment in type 1 diabetes: Unsolved questions on how to select autoantigen and administration route. International Journal of Molecular Sciences. 2020; 21.
50 50. Elding Larsson H, Lundgren M, Jonsdottir B et al. Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr. Diabetes. 2018; 19:410–419.
51 51. Lopes M, Kutlu B, Miani M et al. Temporal profiling of cytokine‐induced genes in pancreatic β‐cells by meta‐analysis and network inference. Genomics. 2014; 103:264–275.
52 52. Sota J, Vitale A, Insalaco A et al. Safety profile of the interleukin‐1 inhibitors anakinra and canakinumab in real‐life clinical practice: a nationwide multicenter retrospective observational study. Clin. Rheumatol. 2018; 37:2233–2240.
53 53. Cabello‐Olmo M, Araña M, Radichev I et al. New insights into immunotherapy strategies for treating autoimmune diabetes. International Journal of Molecular Sciences. 2019; 20.
54 54. Moran A, Bundy B, Becker DJ et al. Interleukin‐1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double‐blind, placebo‐controlled trials. Lancet. 2013; 381:1905–1915.
55 55. Bundy BN and Krischer JP. A quantitative measure of treatment response in recent‐onset type 1 diabetes. Endocrinol. Diabetes Metab. 2020; 3:e00143.
56 56. Buzzetti R, Pozzilli P, Frederich R et al. Saxagliptin improves glycaemic control and C‐peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes. Metab. Res. Rev. 2016; 32:289–296.
57 57. Zhang Z, Yan X, Wu C et al. Adding vitamin D3 to the dipeptidyl peptidase‐4 inhibitor saxagliptin has the potential to protect β‐cell function in LADA patients: A 1‐year pilot study. Diabetes. Metab. Res. Rev.